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Abstract 
 
Cancer is the third leading cause of morbidity worldwide, only surpassed by cardiovascular 
and infectious diseases. In addition, breast cancer is the most common cancer among 
women around the world. Despite increasing research in recent years, real progress 
impacting on translational medicine is scarce. One of the main problems is current 
treatments are harmful for non-cancer cells, hence a more targeted approach may impact the 
efficiency of therapeutics. Nanotechnology promises to make an outstanding contribution to 
targeted therapy by enabling site-specific release of chemotherapeutic agents and because 
of its high stability, high carrier capacity, and greater ability to administer both hydrophilic and 
hydrophobic substances by several routes. 
Nanostructured lipid carriers (NLC) and superparamagnetic iron oxide nanoparticles (SPION) 
appear as hopeful partners in the administration of antineoplastic drugs, such as Paclitaxel 
(PAC). NLCs are biocompatible nanometric sphere-like meshes of lipids which have the 
ability to encapsulate drugs within its pores, travel through the blood stream undetected, 
slowly and controllably releasing the contained drug and delivering it to, and only to, the 
target location. A magnitude smaller, SPIONs are an agglomeration of iron oxides, usually in 
a sphere shape, very prone to modulation. They can be used in diagnostics, therapeutics 
and even both at the same time. 
Herein, SPION-NLC hybrid nanoparticles were studied as possible carriers for PAC. The 
NLC formulation is composed by a spherical nanoparticles suspension with a low 
polydispersity index around 0,237, a mean size diameter of around 375 nm, a zeta potential 
superior to |30| mV and a high encapsulation efficiency of 77%. Despite showing higher zeta 
potential values when stored at room temperature, the nanoformulation proved to be stable 
for at least 2 months at both 4⁰C and 25⁰C. Breast cancer cells, namely MDA-MB-231 cells, 
were used to evaluate the cytotoxicity of the nanoformulations. Internalization of the 
nanoparticles by MDA-MB-231 cells was proved both by an uptake assay and scanning 
electron microscopy (SEM). As demonstrated by methylthiazolydiphenyl-tetratozium bromide 
(MTT) assay SPION-NLC-PAC were efficient in inducing cell death of MDA-MB-231. 
Furthermore, results obtained with flow cytometry regarding apoptosis suggested the 
nanoformulations could indeed be valuable in the breast cancer therapy. 
In conclusion, this nanoformulation still shows a lot of potential for breast cancer therapy. 
Nevertheless, further investigation is required, more cell viability tests should be performed, a 
wider range of concentrations and incubations times should be studied and other breast 
cancer cell lines should also be evaluated.  
 
Keywords: lipid nanoparticles, SPIONs, breast cancer, MDA-MB-231 cells, cell viability. 
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Resumo 
 
O cancro é a terceira causa de mortalidade em todo o mundo, apenas ultrapassada por 
doenças cardiovasculares e infecciosas. O cancro da mama é o cancro mais comum entre 
as mulheres de todo o mundo. Neste sentido, a investigação na área do cancro tem crescido 
e recebido cada vez mais investimentos e apoios. Contudo, avanços sérios e aplicáveis 
estão tão longe ser alcançados como há décadas atrás.  Um dos grandes obstáculos nas 
terapias antitumorais actuais consiste no facto de células saudáveis serem também 
atacadas e danificadas. Com efeito, uma abordagem direccionada a apenas células 
cancerígenas parece ser promissora. A nanotecnologia tem contribuído significativamente 
na evolução das terapias direccionadas uma vez que permite a libertação dos agentes 
quimioterapêuticos num local específico e porque demonstram grande estabilidade, grande 
capacidade de carga e conferem oportunidade de administração de fármacos hidrofilicos e 
hidrofóbicos por diversas vias.  
Os transportadores lipídicos nanoestruturados (TLN) e as nanopartículas 
superparamagnéticas de óxido de ferro (NSOF) surgiram como bons parceiros na 
administração de fármacos antineoplásicos. Os TLNs são esferas lipídicas de escala 
nanométrica biocompatíveis, com capacidade de encapsular fármacos, viajar pela corrente 
sanguínea indetectáveis, libertar o fármaco contido de forma lenta e controlada no local-
alvo. Com um tamanho dez vezes menor, as NSOF são aglomerados de óxido de ferro, 
normalmente de forma esférica, muito facilmente modulados. Tem a capacidade de realizar 
uma multitude de funções, desde diagnóstico a terapia, e até mesmo ambos 
simultaneamente. 
Neste projecto, nanopartículas híbridas de TLNs e NSOFs foram estudados como possíveis 
transportadores  de paclitaxel (PAC). A nanoformulação é composta por uma suspensão de 
nanopartículas esféricas com baixo índice de  polidispersão, cerca de 0,237. A média do 
diâmetro das partículas é aproximadamente 375 nm e o potencial zeta é superior em módulo 
a 30 mV. As nanopartículas apresentam também uma elevada eficiência de encapsulação 
do fármaco, cerca de 77%. Apesar das nanopartículas armazenadas a temperatura 
ambiente apresentarem valores de potencial zeta mais elevados,  tanto as armazenadas a 
4⁰C como a 25⁰C provaram manter-se estáveis por pelo menos 2 meses. Células de cancro 
da mama, especificamente células MDA-MB-231, foram utilizadas para testar a 
citotoxicidade das nanoformualções. A internalização das nanopartículas por parte das 
células MDA-MB-231 foi comprovada através de ensaios de uptake e por microscopia 
electrónica de varrimento (MEV). Nos ensaios com brometo de 3-(4,5-dimetiliazol-2- il)-2,5-
difeniltetrazólio em células MDA-MB-231 verificou-se citotoxicidade por parte das 
nanopartículas de interesse. Da mesma forma, os ensaios de apoptose realizados por 
citometria de fluxo demonstraram que a nanoformulação sugerida poderá ser valiosa na 
terapia contra o cancro da mama. 
Em suma, a nanoformulação desenvolvida apresenta ainda grande potencial para aplicação 
em terapia do cancro da mama. Porém, são necessários mais estudos, mais testes que 
avaliam viabilidade celular devem ser realizados e uma maior gama de concentrações e 
tempos de incubação devem ser testados. É igualmente importante avaliar outras linhas 
celulares de cancro da mama. 
 
Palavras-chave: nanopartículas lipídicas, NSOFs, cancro da mama, células MDA-MB-231, 
viabilidade celular. 
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Chapter 1 - Introduction 
 
1.1 NANOTECHNOLOGY AND NANOMEDICINE 
 
In 1959, the renowned physicist and Nobel Prize-winner Richard Feynman 
envisioned the possibility to manipulate atoms and molecules using high precision 
instruments. Later in 1981, the term nanothecnology was first applied by the engineer 
Eric Drexler when describing in more detail Feynman’s speech 1,2. Nanotechnology 
represents the understanding and control of matter at dimensions between 
approximately 1 and 100 nanometers, where unique phenomena enable novel 
applications 1. As the particle size diminishes the surface area to volume ratio 
increases, promoting changes in its physicochemical properties and environmental 
interactions reaching a scale at which quantum effects dominate properties of 
materials 3.  
Nanotechnology has proven to benefit society in a wide variety of areas, it has 
revolutionize a number of technology and industry sectors, such as electronics, 
energy, textiles, military, and others 4. However, the wide range of studies on 
nanotechnology focus mainly on nanomedicine, in the last 20 years over 14 000 
studies were published in the field. Nanomedicine is the medical application of 
nanotechnology, presenting new and innovative interventions and treatments. The 
three main sectors of nanotechnology - nanomaterials, molecular nanotechnology 
and biotechnology - might be an imperative tool for future medicine with application in 
diagnostics to therapeutics 2. 
The nanoscale effects and increased surface area have triggered an investigation of 
nanomaterials as promising tools for the advancement of diagnostic biosensors, drug 
and gene delivery, and biomedical imaging 5,6. Nanodiagnostics can possibly work at 
a cellular and even sub-cellular level, assuming extreme importance in the 
continuous goal to identify a disease as early as possible. In fact, a diversified set of 
nanoparticles has exhibited a prominent  potential for detecting disease markers, 
fragments of viruses, pre-cancerous cells, specific proteins, antibodies, and others 6.  
Superparamagnetic iron oxide nanoparticles coated with a recognition molecule 
represent an useful improvement to the typical Magnetic Resonance Imaging (MRI) 
technique since it provides a localized contrast 7. Optical detection is also possible 
when a fluorescent molecule is encapsulated or used in the functionalization of a 
nanoparticle 8. Quantum dots have also been thoroughly studied due to their unique 
physiochemical properties, conferred by a quantum confinement effect 9. These types 
of nanoparticles show a wide range of applications such as molecule tracking and 
fluorescent imaging 10,11. Nanosensors are another important example of the 
application of nanotechnology in diagnostics. Sensors are able to detect events or 
changes in the environment and provide a corresponding output, consisting in 
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electrical or optical signals. In this case, a nanosensor recognizes a specific molecule 
or a variation in the environment and transduces a signal that can be a magnetic 
resonance change, a release of light, or an absorbance shift due to agglomeration 12–
14. 
Several nanomaterials are currently under intense investigation, including nanowires, 
quantum dots, and iron oxide, in order to develop nanosensors constructed to detect 
disease. In particular, functionalized nanowires have been able to detect disease 
indicators and cancer cells, and to measure blood chemistry. In addition a sensor 
using billions of carbon nanotubes has been developed by MIT and Harvard 
researchers. These nanotubes were functionalized with antibodies that attach to 
cancer cells and appear to be sensitive enough to indicate the entrapment of a single 
cancer cell 15. 
Identically, nanotechnology has demonstrated great potential in the area of 
therapeutics being able to improve drug’s solubility and stability, prolong drug half-
lives in plasma, minimize target effects, and concentrate drugs at the desired target 
site. Consequently, the term nanotherapy emerged as the use of novel nanoscale 
agents capable of a therapeutic effect at specific types of cells or extracellular 
locations 16,17. Mostly, nanoparticles are applied as delivery agents, acting as 
vehicles for drugs, light-emitting or heat-releasing molecules, that can reach the 
targeted site in such a way that allows a directed treatment with minimal damage to 
bystander cells. Another major advantage for the application of nanotechnology in 
therapy is the possibility for controlled release of therapeutic compounds. Substantial 
investigation has been done in order to incorporate therapeutic agents into 
biocompatible nanodevices, such as liposomes, micellar systems, polymer 
nanoparticles, inorganic nanoparticles, nanotubes, and dendrimers 16,17.  
Moreover, nanoparticles can also be engineered to stimulate body’s innate repair 
mechanisms. Artificial activation and control of adult stem cells are an important step 
in this area of investigation. Magnetic nanoparticles and enzyme-sensitive 
nanoparticle-coatings that target brain tumors, polymeric nanoparticles coated with a 
red blood cell membrane (nanosponges) which act as decoys and intercept toxins in 
the blood stream, smart nanoparticles probes for intracellular drug delivery and gene 
expressing imaging, quantum dots that detect and quantify human breast cancer 
biomarkers, carbon nanotubes which can convert light into tightly focused sound 
waves, among others are just a few of the advances already achieved in 
nanotherapy 18,19. 
Nanotheranostics emerged in recent years as the simultaneous implementation of 
nanotechnology for diagnosis and therapy. The recent advances in the area of 
nanotechnology has enabled a new generation of different types of nanomaterials to 
be useful to nanotheranostics applications with the intention to diagnose and treat the 
disease at its earliest stage, enhancing the prospective of cure. By combining both 
therapeutic and diagnostic functions in one delivery formulation, nanotheranostic 
agents enable disease diagnosis, therapy and real-time monitoring of treatment 
progress and efficacy, with only one pharmaceutical agent. High variability and 
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modification possibilities makes nanoparticles greatly desired for this approach 10,20–
22. Monitorization of biodistribution, drug release kinetics and therapeutic efficacy can 
be achieved by non-invasive imaging methods, such as magnetic resonance imaging 
(MRI), computed tomography (CT), positron emission tomography (PET) and 
ultrasonic (US) imaging techniques. In combination with therapeutic strategies 
namely chemotherapy, gene therapy, photodynamic therapy (PDT), and photodermal 
therapy, nanotheranostics approaches can be acomplished 23. 
Nanotherapy is widely studied with respect to the treatment for cancer, a disease 
with no predicted cure in the past. In fact, more than 80% of USA Food and Drug 
Administration approved and investigated drug nanocarriers are intended for cancer 
treatment 24.  
 
1.1.1 NANOMEDICINE IN CANCER 
The human body is made up of trillion of living cells, that grow, divide and eventually 
die, being replaced by new cells. This is a process that is tightly regulated by their 
DNA machinery. However, when this orderly process fails, cells become abnormal, 
they persist in environments prone to cell death and new cells are formed when they 
are not needed. These cells can grow and divide uncontrollably and may develop the 
potential to invade or spread to other parts of the body. In this case, these cells are 
considered cancerous cells 25,26. In fact, cancer is a genetic disease since it is 
caused by changes in genes that control several cell functions. These changes can 
be inherited or acquired during the individual’s lifetime, they can be the result of 
errors in cell division or DNA damages caused by exposure to different 
environmental factors 25,27.  
Remarkable progress has been accomplished towards the understanding of 
hallmarks of cancer progression and treatment. However, cancer continues to be the 
leading cause of death of the twenty-first century28. Basic biological processes that 
have an important role in the development of cancer have been extensively studied, 
researchers showed disturbances in growth factor binding, signal transduction, gene 
transcription control, cell-cycle checkpoints, apoptosis, and angiogenesis. New 
discoveries in cancer biology prompted the search for anticancer drugs, which lead to 
the design and development of a record number of novel compounds, from which 
some are currently being used in cancer therapy. Furthermore, the new therapeutic 
approaches are based on the rectification of the damage caused to the genes, by 
stopping the blood supply to the tumor or by destroying cancer cells. Despite all this 
new information and compounds there are still limitations to this kind of therapy. For 
instance, pharmacological active cancer drugs reach the tumor site with poor 
specificity and dose-limiting toxicity 29.  
Nanotechnology is a rapidly growing field and promises to make an outstanding 
contribution to cancer treatment strategies by enabling site-specific release of 
chemotherapeutic agents, based on their physiochemical characteristics and 
4 
 
biological attributes 30. Furthermore, nanoparticle formulations show high stability, 
elevated carrier capacity, and greater ability to administer both hydrophilic and 
hydrophobic substances through several routes 31. Advances in synthetic chemistry 
allowed the development of different biological nanomaterials that can be used for 
numerous biological therapies, including drug delivery, cancer diagnosis, treatment 
and imaging 32.  
Nanoparticle systems can possibly revolutionize cancer therapy, mainly due to their 
ability to reduce the tumor or related events without damaging healthy tissues. 
Moreover, nanoparticles offer higher efficacy, lesser side effects, site specificity, 
efficient delivery, and overcome multidrug resistance (MDR) 33. Nanoparticle-based 
drug delivery systems such as liposomes, dendrimers, diamondoids, quantum dots 
(QD), viral nanoparticles, and carbon nanotubes have shown encouraging results in 
cancer therapy and drug delivery 34.  
Table 1 - Nanoparticles for cancer therapy approved or in clinical trials. 
 
Name Nanocarrier Formulation Indication Status Ref. 
CYT-6091 
Inorganic 
nanoparticle 
TNFα-PEG-gold Solid tumors Phase I 
35
 
Doxil Liposome 
Liposomal 
doxorubicin 
Ovarian, Breast 
Cancer 
Approved 
1995 
36
 
NKTR-102 Micelle 
PEG-micelle 
Irinotecan 
Colorectal, Breast 
Cancer 
Phase III 
37
 
Abraxane 
Protein 
nanoparticle 
Paclitaxel-
albumin 
Metastic Breast 
Cancer 
Approved 
2005 
38
 
Genexol-PM 
Polymeric 
micelle 
Miceller 
Paclitaxel 
Breast, Lung, 
Pancreatic Cancer 
Phase II-IV 
39
 
Xyotax 
Polymer-drug 
conjugate 
Paclitaxel-poly-
L-glutamic acid 
Breast, Ovarian 
Cancer 
Phase III 
40
 
Oncaspar 
Polymer-drug 
conjugate 
PEG-L-
asparaginase 
Acute 
Lymphoblastic 
Leukemia 
Approved 
2006 
41
 
BIND-014 
Polymer 
nanoparticle 
Docetaxel-
PLGA/PLA-PEG 
with targeting 
ligand 
Nonsmall Cell Lung 
Cancer, Prostate 
Cancer 
Phase II 
42
 
Zevalin 
radio-
immunoconjugat
e 
anti-CD20 
conjugated 
toytrium-90 or 
indium-111 
Non-Hodgkin's 
Lymphoma 
Approved 
2002 
43
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The biggest advantage of using nanotechnology in cancer treatments is refined 
targeting. Targeting strategies can rely on ligand-mediated specific interaction 
between nanoparticles and cancer cell surface (active targeting) or by taking 
advantage of the abnormal tumor microenvironment (passive targeting). Ligand-
targeted nanoparticles are expected to deliver cytotoxic agents selectively and 
specifically to tumor cells via receptor-mediated endocytosis, thereby enhancing 
intracellular drug accumulation. Antibodies, folate, growth factors, and cytokines are 
some of the several tumor-targeting ligands that can be used to facilitate the uptake 
of carriers into target cells 44. Furthermore, monoclonal antibodies and antibody 
fragments are able to reduce immunogenicity and improve pharmacokinetics 45. 
Passive targeting depends significantly of nanoparticles’ properties, such as size, 
charge, surface nature, and circulation half-time 46. Additionally, passive targeting to 
a tumor can be achieved due to the enhanced permeability and retention effect 
(EPR) 47. EPR effect is the property by which molecules of certain sizes tend to 
accumulate in tumor tissue. 
As previously depicted, nanotechnology-based approaches can also be applied to 
diagnosis, showing a great potential for improving the efficiency of early detection of 
precancerous and neoplastic lesions. Nanomaterials have long-term stability and 
allow in vitro and in vivo diagnosis with superior sensitivity than conventional imaging 
48,49. Additionally, combination of existing optical imaging technologies with 
sophisticated nanoparticle-based optical contrast agents for high-resolution in vivo 
cancer imaging has been successfully achieved. However, developing reliable early 
detection of tumors from blood-serum, other biological fluids, or any sample obtained 
through minimal or non-invasive procedures remains imperative 50. 
Notably, there are several nanoparticle therapeutics directed to cancer treatment 
approved by the USA Food and Drug Administration (FDA) or in clinical trials. A small 
portion is summarized in Table 1. 
 
1.1.2 BREAST CANCER 
There are over 200 different types of cancer each with its own biology, diagnosis and 
treatment 51. Breast cancer is the most common cancer among women worldwide 
and in 2015 approximately 300 000 new cases of breast cancer were diagnosed in 
women in the USA 52,53. In men, breast cancer incidence is rare, with only 2 350 new 
cases of breast cancer diagnosed in the USA during 2015 52. 
In order to better understand breast cancer it is important to have some basic 
knowledge about the normal structure of women’s breasts (Figure 1). Female’s 
breasts are made up mainly of lobules (also known as milk-producing glands), ducts 
(connective tubes responsible for the transportation of milk from the lobules to the 
nipple) and stroma (fat and connective tissue surrounding the ducts and lobules, 
blood vessels, and lymphatic vessels) 54,55. Normal breast tissue goes through 
hormonal-dependent cycles of imbalance between proliferation and apoptosis during 
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menstrual periodicity, pregnancy and lactation, that when not properly regulated may 
result in the development of tumors. Breast cancer usually begins in the cells of the 
lobules or the ducts, however in some cases can also begin in the stromal tissue 
52,54–56.  
Human breast cancer is classified according to different systems: (1) the histological 
cell type, (2) the extent of invasion into surrounding tissues, (3) the size of the tumor, 
and (4) if it has spread to nearby lymph nodes. For instance, if the tumor has not 
developed the ability to spread outside the breast it is considered non-invasive (also 
known as carcinoma in situ), otherwise it is classified as invasive. Even though an 
invasive breast cancer has the ability to spread out it does not necessarily means it 
will. The cancer usually spreads out through the lymph nodes (small glands that filter 
foreign substances from the body) facilitating its access to the bloodstream. The 
more lymph nodes affected by breast cancer cells, the higher are the chances for the 
cancer to be found in other organs as well. However, not all women with breast 
cancer cells in their lymph nodes present signs of metastases, and cancer cells can 
be detected in other parts of the body in women with no cancer cells in the lymph 
nodes 52,54–56.  
There are many risk factors for developing breast cancer, including being female, 
obesity, infrequent exercise, alcohol consumption, being under hormone replacement 
therapy during menopause, having a late pregnancy or none at all, age, among 
others 27,57. Family history is also an important risk factor, about 5 to 10% of breast 
cancer cases are thought to be hereditary. The most common cause of hereditary 
breast cancer is an inherited mutation in the Breast Cancer Gene 1 and 2 (BRCA1 
and BRCA2 genes). In normal cells, these genes help prevent cancer by making 
proteins that control and regulate their normal growth 57,58.  
Figure 1 - Schematic representation of a female breast 
58
. 
7 
 
The first symptom noticed by women with breast cancer is normally a lump or an 
area of thickened tissue in the breast, but there are other symptoms such as, 
changes in size or shape of one or both breasts, abnormal discharge from the 
nipples, lumps or swelling on the armpits, dimpling on the skin of the breasts, a rash 
on or around the nipples, changes in the appearance of the nipples, pain in the 
breasts or armpits, and others 59. However, even when none of the symptoms are 
presented, women should do routine breast cancer screenings (mammograms and 
breast ultrasounds). If the physician suspects of breast cancer diagnosis a biopsy 
should be performed in order to assess if the presence and type of breast cancer. 
There are four types of biopsy: excisional biopsy, where an entire lump of tissue is 
removed; incisional biopsy, in which only a part of a lump or a sample of tissue is 
collected; core biopsy, where a wide needle is used to remove tissue, and fine-
needle aspiration biopsy, used to remove fluid from the lymph nodes or to drain a 
benign cyst without removing any tissue 60. 
When choosing treatment the doctor must consider the cancer’s stage and grade, the 
general health of the patient and whether the woman has been through menopause 
or is pregnant at the time 59,61. To better assess future treatments a few tests are 
performed on the biopsy sample of the patient. In addition, these tests allow the 
physician to understand how quickly the cancer may grow, how likely it is to spread 
through the body and how likely it is to recur. Estrogen and progesterone receptor 
test measures the amount of these hormone receptors in cancer tissue, if there are 
more receptors than normal the cancer is described as estrogen and/or progesterone 
receptor positive. This type of breast cancer has a tendency to grow more quickly 
than others. Results from this test also provides valuable information about the 
viability of a treatment that blocks estrogen and/or progesterone. Human epidermal 
growth factor type 2 receptor (HER2) test is a laboratory test that measures the 
amount of HER2 gene and HER2 protein in a tissue sample, if their levels are higher 
than normal the breast cancer is described as HER2 positive. This type of breast 
cancer tends to grow quickly and spread to other parts of the body, and is usually 
treated with drugs that target HER2 proteins, such as trastuzumab and pertuzumab. 
Although it is not routinely done, a multigene test can also be performed in order to 
study the activity of many genes at the same time in a tissue sample. These results 
may help predict cancer behavior. In conclusion, breast cancer may be described as 
Hormone Receptor Positive, Hormone Receptor Negative, HER2 Positive, HER2 
Negative or Triple negative (estrogen receptor, progesterone receptor and HER2 
negative) 62,63.  
Treatment can be local or systemic. Local therapy intends to treat the tumor at the 
site, having no effect on the rest of the body, while systemic therapy consists in the 
oral or intravenous administration of drugs which can reach cells anywhere in the 
body. Surgery and radiotherapy are considered local therapies whereas 
chemotherapy, endocrine therapy and targeted therapy are described as systemic 
therapies 64,65. 
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  1.1.2.1 Surgery  
Surgery is usually the first treatment considered when breast cancer is diagnosed. 
Surgery has the main goal of removing the tumor and its margins for future analysis. 
After it has been removed and studied it is possible to tell if the tumor had clear 
margins, meaning that there are no cancer cells in the tissue surrounding the tumor 
66. There are different options of surgery depending on the size of the tumor, whether 
it has spread out to other parts of the body, the size of the breasts and patient’s 
personal wishes and feelings. If the tumor and surrounding tissue may be excised 
without removing the entire breast, a lumpectomy will be performed (also known as 
breast-conserving surgery). On the other hand, if the whole breast has to be removed 
the doctor will recommend a mastectomy. A mastectomy can also be performed as a 
prophylactic measure in patients with high risk of developing breast cancer. Another 
prophylactic measure currently used is the removal of the ovaries since it will lower 
the amounts of estrogen in the body diminishing the risk for developing breast cancer 
67,68.  
Under certain circumstances, patients have the opportunity to decide between a 
mastectomy or a lumpectomy followed by radiation. The latter tends to be equally 
effective when the tumor is restricted to one site of the breast and is under four 
centimeters. It is also imperative that the tumor present clear margins. Possible side 
effects of any of these surgeries are pain, temporary swelling, tenderness, and hard 
scar tissue that forms in the surgical site. Bleeding and infection at the surgery site 
are also possible. During or after surgery women normally undergo reconstructive 
surgery to restore the breasts appearance. Nevertheless, many women decide not to 
have reconstruction or opt for a prosthesis instead 68–70.  
 
1.1.2.2 Radiotherapy  
Radiotherapy uses high-energy rays or particles that permanently damage the DNA 
of cancer cells, destroying them. However, nearby tissue also suffers temporary cell 
damage, causing side effects such as sore skin, fatigue and chest pain. In breast 
cancer, radiotherapy is usually administered after breast-conserving surgery to lower 
the chances of reappearance in the breast or in the nearby lymph nodes. Radiation is 
also recommended after a mastectomy when the tumor is larger than 5 cm or it has 
spread to the lymph nodes 71–73.  
There are three main types of radiation, the most common is the external radiation 
(also known as external beam radiation) where a source of radiation is focused 
outside the body on the area affected by the cancer. The extent of radiation will 
depend on the type of surgery the patient was subjected to and whether any lymph 
nodes were affected. If the patient had a mastectomy where no lymph nodes had 
cancer, radiation will be targeted at the chest and the places where any drains exited 
the body. On the other hand, if a breast-conserving surgery was performed the whole 
breast will be getting radiation with an extra boost after the treatment is complete in 
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order to prevent recurrence. This boost is delivered by the same machine, though the 
beams are aimed directly at the area around the surgery site. If cancer is found in the 
lymph nodes under the arm, this area will also be subjected to radiation. Another way 
to deliver radiation is by seeds or pellets placed into the breast tissue next to the 
tumor, this is internal radiation (also known as brachytherapy). Internal radiations can 
be delivered using multiple small tubes or catheters that are inserted into the breast 
around the area where the tumor was removed. Each day, for short periods of time, 
radioactive pellets are inserted in the tubes. Once the treatment is complete the 
tubes and the pellets are removed. This technique is known as interstitial 
brachytherapy. Moreover, brachytherapy can be intracavitary, where a balloon-
catheter device can be used to deliver radiation. This tube with a balloon is placed in 
the area where the tumor was and it is filled with fluid so it remains in place. 
Radioactive pellets are placed down through the tube and into the device for a short 
time. At the end the balloon-catheter device and pellets are removed. The latter is the 
most commonly used nowadays and it is considered a form of accelerated partial 
breast radiation. There is also the option of receiving radiation during surgery, known 
as intraoperative radiation or intrabeam radiotherapy. An applicator is positioned 
inside the breast after the tumor is removed, furthermore a radioactive source is 
placed inside this applicator for ten to thirty minutes, giving a high dose of radiation 
directly to the tissue around the cancer. This technique is fairly new and there is no 
consensus between doctors if this is a good alternative to external or internal 
radiotherapy. Besides the curative intent, radiotherapy may also be given as a 
palliative treatment to relieve symptoms and reduce the suffering cause by the 
cancer 71,72.  
In some cases, radiotherapy can be combined with hyperthermia (also known as 
thermotherapy). An energy source, such as ultrasound or microwave, is used to heat 
cancer cells which can increase their sensitivity to radiation. This course of treatment 
is still under study and it is not available everywhere 74.  
 
1.1.2.3 Chemotherapy  
Chemotherapy involves the use of cancer-killing drugs that travel through the 
bloodstream to reach cancer cells and disrupt their growth. However, these drugs 
cannot distinguish between normal and cancer cells, having an effect in every 
actively growing and dividing cell. Consequently, these drugs will have a poisonous 
consequence on the body causing problems that include fatigue, hair loss, mouth 
sores, nausea and low blood cell counts. Furthermore, chemotherapy can affect cells 
from the bone marrow leading to an increased chance of infections and easier 
bruising and bleeding. Before any type of chemotherapy is chosen the doctor must 
consider the tumor type, tumor size, tumor grade, number of lymph nodes involved 
and its degree of involvement, and the risk for metastasis 75,76. There are many cases 
where chemotherapy may be recommended, it can be administered as main 
treatment in cases where the cancer has come back or has spread outside the breast 
and underarm area, and it can be associated with surgery. When it is used in patients 
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with no evidence of cancer after surgery it is called adjuvant therapy since it is used 
to kill any cancer cells that may have been left behind or spread, but have gone 
unnoticed. Using this procedure the risk of breast cancer recurrence is highly 
reduced. When chemotherapy is administered before surgery it is called neoadjuvant 
therapy. Neoadjuvant chemotherapy has two main benefits, it can shrink the tumor 
allowing a less extensive surgery and it can give precious information on the 
response of the tumor to the treatment. For example, if the first set of drugs do not 
shrink the tumor, another combination of drugs will be needed. Chemotherapy may 
also be used as a palliative measure to relieve symptoms in cases where a cure is 
not possible 75–78.  
In most cases a combination of drugs has been proved to be more effective, however 
there is no single combination that has shown to be the best. Furthermore, several 
clinical trials still compare today’s most effective treatments to new ones in the hopes 
of improving breast cancer treatment. Anthracyclines and taxanes are the most 
common drugs used in early stage breast cancer, usually in combination with other 
drugs. On the other hand, when the disease is advanced it is often treated by one 
single drug, still some combinations like carboplatin or cisplatin plus gemcitabine are 
commonly used to treat advanced breast cancer 75,76.  
 
1.1.2.4 Endocrine Therapy  
Hormones are regulatory biochemical compounds produced by the body that control 
the growth and activity of normal cells. Female hormones, estrogen and 
progesterone, are mainly produced in the ovaries, but can also be produced in 
smaller amounts by the adrenal cortex. Estrogen is responsible for the regulation of 
the menstrual cycle and the reproductive system, and the development of secondary 
sex characteristics. Progesterone plays an important role in the menstrual cycle and 
during pregnancy, and promotes the development of the mammary gland. However, 
both of them can stimulate the growth of breast cancer cells. Hormone-sensitive 
breast cancer cells contain proteins known as hormone receptors. When hormones 
bind to these receptors they are activated, which in term will alter the expression of 
some specific genes, leading to the stimulation of cell growth. Therefore, endocrine 
treatment intends to lower the levels of female hormones or block their effects. 
However, treatment is more likely to succeed in hormone receptor-positive cancer 
cells, either estrogen receptor-positive or progesterone receptor-positive. Tamoxifen 
is a well-known estrogen receptor modulator developed over 30 years ago. It is a 
selective estrogen receptor modulator (SERM) since it acts as an anti-estrogen in 
breast cells, but it acts like an estrogen in other tissues (uterus, bones, etc.) 79,80.  
Hormone therapy can be applied in different situations, before surgery to shrink large 
or locally advanced tumor in the breast, after surgery to lower the risk of 
reappearance, if the patient cannot have surgery to stop the growth and shrink the 
tumor, and if the cancer comes back or spreads to control or shrink a breast cancer 
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that has metastasize. Although endocrine therapy is a good option to treat breast 
cancer it can never get rid of it completely 79,80.  
 
1.1.2.5 Targeted Therapy  
The biggest problem with conventional cancer therapies is that they are not able to 
distinguish between normal and cancer cells, attacking both of them. To overcome 
this dilemma many studies have been carried out. The more knowledge about 
genetic alterations that lead to cancer the easier it becomes to develop new drugs 
that specifically target these changes. These targeted drugs present different 
mechanisms of action and fewer side effects than conventional chemotherapy drugs 
81,82.  
For instance, researchers have found that some breast cancer cells have extremely 
high levels of HER2, a growth-promoting protein, on their surface stimulating their 
growth and metastases. With this new information several drugs have already been 
developed to target this protein. Trastuzumab is one of the most largely used. It is a 
man-made version of a very specific immune system protein that attaches to HER2 
and, as a result, slows the tumor growth. It may also stimulate the immune system 
increasing its efficiency in attacking cancer cells 81,82. 
  
1.1.2.6 Nanotherapy 
Within targeted therapies nanotherapy is definitely the most valuable. Nanotherapy 
by definition is the use of nanoscale strategies to produce therapeutic effects. 
Regarding breast cancer there are many nanoparticles under investigation but few 
are the ones that are approved by the USA FDA and European Medicines Agency. 
Nab-paclitaxel is a nanoparticle formulation approved by the FDA and already used 
in the treatment of breast cancer. Nab-paclitaxel is an alternative formulation where 
paclitaxel is bound to albumin nanoparticles and it proved to be better at reaching 
tumors than solvent-based Paclitaxel 83,84. A non-pegylated form of liposomal 
encapsulated doxorubicin, known as Myocet, is also routinely used in the treatment 
of metastatic breast cancer. Myocet is currently approved in Europe and Canada, 
although it has not been approved by the FDA in the USA 85,86. 
 
1.2 NANOFORMULATION 
 
1.2.1 LIPID NANOPARTICLES  
Lipid nanoparticles were first developed in the early 1990s. Today they are one of the 
most attractive nanoparticles for drug delivery, due to the combination of some 
characteristics, such as particle size, low toxicity, physical stability, controlled release 
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properties, high drug load and excellent tolerability 87.  Lipid nanoparticles are 
prepared as colloidal arrangements with a solid lipid matrix being held together by a 
surfactant. Its constituents are excipients recognised as safe and known to be 
biocompatible, therefore these nanoparticles are Generally Recognized as Safe 
(GRAS) 88.  
Various techniques to produce lipid nanoparticles have been described. High 
Pressure Homogenisation (HPH) is a method that can be performed at both high (hot 
HPH) and low (cold HPH) temperatures. In the first the lipid and the drug are blended 
together and later combined with the surfactant at the same temperature. A hot pre-
emulsion develops after high speed stirring of the solution, with the help of a 
temperature controlled high pressure homogeniser a nanoemulsion appears. Lipid 
nanoparticles are produced by the recrystallization of the nanoemulsion after it cools 
down to room temperature. Cold HPH synthetizes lipid nanoparticles after melting 
together both lipid and drug and subsequently placing the mixture in liquid nitrogen. 
Solid lipid microparticles appear and undergo high speed stirring in a cold aqueous 
surfactant solution, developing a pre-suspension. This pre-suspension is 
homogenised at room temperature and finally the lipid nanoparticles arise. 
Microemulsion is another technique where the solid lipids are melted and then 
dissolve the drug. A surfactant-cosurfactant solution at a temperature above the 
melting temperature of the solid lipids is later added with mild agitation in order to 
attain a microemulsion. Maintaining mild agitation, the micremulsion is dispersed in 
cold water developing ultrafine nanoemulsion droplets that immediately crystallize 
forming lipid nanoparticles. In solvent emulsification-evaporation the lipids are 
dissolved in a water-immiscible organic solvent and, under continuous stirring, 
emulsified in an aqueous phase containing surfactants. During the emulsification the 
organic solvent evaporates and the lipid precipitates producing lipid nanoparticles. To 
ensure thermodynamic equilibrium of liquids, water-miscible organic solvents 
saturated with water are employed in solvent diffusion. The transient oil-in-water 
emulsion is transferred into water under continuous stirring, leading to solidification of 
the dispersed phase and lipid nanoparticles synthesis due to diffusion of the organic 
solvent. Solvent injection is another common method in the production of lipid 
nanoparticles. Lipids are dissolved in a water-miscible solvent or mixture and later, 
with the help of an injection needle, the solution is rapidly injected into an aqueous 
surfactant solution. The double emulsion method is based on emulsion-evaporation 
method, and it is commonly known as water in oil in water (w/o/w). This technique 
uses a stabilizer during hydrophilic drug encapsulation in the internal water phase of 
a w/o/w double emulsion, avoiding drug partitioning to the external water phase 
during solvent evaporation. Another well-known technique is the high speed stirring 
and/or ultra-sonication where lipid microparticles are produced by spray congealing 
and are the used to produce lipid nanopellets by high speed stirring or sonication. 
Lastly, there is the emulsification-sonication method where the lipids are melted at 
temperatures slightly above their melting point. The drug dissolves in the lipids and 
an aqueous surfactant at the same temperature is later added to the solution. With 
the help of a high shear homogenization device the solution is homogeneously 
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dispersed and the obtained emulsion is then subjected to ultrasonication, leading to 
the synthesis of lipid nanoparticles 88–90. 
There are mainly two types of lipid nanoparticles, Solid Lipid Nanoparticle (SLN) and 
Nanostructured Lipid Carriers (NLC) 90–92. SLNs are prepared using solid lipids at 
room and body temperature and stabilized by surfactants. They are composed of 0.1-
30% (w/w) solid lipid dispersed in an aqueous solution of 0.5-5% (w/w) surfactant 93. 
These nanoparticles range from 40 to 1000 nm and can be used for target-specific 
controlled drug delivery by several administration routes. SLNs are able to 
incorporate both lipophilic and hydrophilic drugs because of their great water content 
88,91. Henceforth, they display a good physiochemical stability, protection and 
controlled release of the encapsulated drug, low toxicity, organic solvent free 
synthesis and an easy scale-up 88. However due to their extremely ordered matrix 
and crystalline imperfections they show low encapsulation efficiency and little stability 
during storage, notably during storage polymorphic transitions may happen because 
of crystalline rearrangements  leading to drug expulsion. Gelation of the dispersion 
and particle growth may also occur during storage 88,90,93,94. 
These limitations were surpassed by the development of another set of lipid 
nanoparticles, the NLCs. Therefore, a liquid lipid was added, allowing a less ordered 
lipid matrix and, consequently, higher encapsulation of the active compound (Figure 
2) 95. These nanoparticles show a targeted and controlled drug release and can also 
be easily adapted to large scale production 90,92,93,96. As a result nanoresearchers 
have shown a keen oncological interest in NLCs, notably a wide variety of in vitro and 
animal models assays have been conducted successfully and reported in literature 
97–104. 
 
1.2.2 MAGNETIC NANOPARTICLES 
Magnetism is a physical phenomenon mediated by magnetic fields. A magnetic field 
consists of imaginary lines of flux coming from the motion of electrically charged 
Figure 2 - Lipid crystalline matrix representation of SLN (a) and NLC (b) 
88
. 
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particles, such as protons, electrons, and neutrons (despite being neutral, neutrons 
are basically smaller electrically charged particles) 105.  The magnetic field of an 
object can create a magnetic force on other objects with magnetic fields. Every 
material is influenced to some extent by a magnetic field, thereupon every material 
has an intrinsic property called magnetization, M. Magnetization is the vector sum of 
all its individual components’ magnetic moments. When a material is placed in 
contact with an external magnetic field, H, its magnetization creates a larger induced 
magnetic field, B, in a phenomena called magnetic induction, where μ0 represents 
the permeability of free space 106,107: 
           
Depending on the magnetic susceptibility of magnetic material, these can be 
classified in two categories, paramagnetism, when it is positive, and diamagnetism, 
when it is negative. According to Lenz’s law, which states “If an induced current 
flows, its direction is always such that it will oppose the change which produced it”, 
every material presents an innate diamagnetic property, even though it is very small 
in most cases 108,109. Regardless, some materials display such a positive magnetic 
susceptibility that it will overpower its diamagnetic properties, in this case the material 
shows paramagnetism 110. Another method of classification reckons on the relative 
ordering of the magnetic moments contained in a material. When there are no 
magnetic moments the material does not display diamagnetic properties. In a 
paramagnetic material each magnetic moment is randomly oriented due to thermal 
energy. However, when a decrease in temperature occurs, the magnetic interaction 
between the magnetic moments overcomes the thermal energy’s influence, 
generating a characteristic ordered state. If the ordering is parallel and happens 
below the Curie-Weiss temperature we are in the presence of a ferromagnetic 
material. On the other hand, if the ordering antiparallel and occurs below Néel 
temperature the material shows antiferromagnetic properties. These critical transition 
temperatures are individual to each material’s chemistry and magnetic 
characteristics. Ultimately, there is a variant of antiferromagnetism where each 
interacting pair of magnetic moments have different magnitudes 106,108–110. 
When a magnetic material ranges from an atomic scale to a couple dozens of 
nanometers it starts behaving as a single giant magnetic domain, becoming similar to 
paramagnets 111. Henceforth, magnetic nanoparticles mostly display 
superparamagnetism and are of keen interest to researchers. Usually, there are 
three functional parts in a magnetic nanoparticle, a magnetic core, a surface coating, 
and a functionalized outer coating. The magnetic core it is at the center of the 
nanoparticle and allows the manipulation of the nanoparticle in the presence of an 
external magnetic field 112,113. Magnetic nanoparticles may be synthetize by physical 
vapour deposition, mechanical attritioning, and via chemical route 114.  There are a 
wide variety of applications for these types of nanoparticles, including magnetic fluids 
recording 115, catalysis 116, biotechnology/biomedicine 117, material sciences, photo 
catalysis 118, electrochemical and bioeletrochemical sensing 119, microwave 
absorption 120, MRI 121, medical diagnosis, data storage 122, environmental 
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remediation 123, among others. In biological applications, hyperthermia stands out, 
since it is a type of cancer treatment. Localized tissue is exposed to high 
temperatures, when it goes above 40⁰C the natural enzymatic processes become 
more susceptible to the effect of radiation or chemotherapy while inducing apoptosis. 
Above approximately 45⁰C human cells die of necrosis in a process known as 
thermoablation 124.  
Furthermore, superparamagnetic nanoparticles have demonstrated to be a great 
advantage for therapeutics. In emphases, superparamagnetic iron oxide 
nanoparticles (SPIONs) show no agglomeration and no considerable cytotoxic 
effects, being a good option for cancer therapy 125–127. 
 
1.2.3 PACLITAXEL 
Taxanes are an important class of antitumor agents that act by stabilizing 
microtubules, leading to inhibition of cell proliferation. Paclitaxel (PAC) is a well-
known taxane that was first identified as a crude extract of the Taxus brevifolia in 
1966. It was later purified in 1969 and its structure was finally published in 1971. 
Approval from FDA marked a milestone in the management of breast cancer 
because it was the first agent to demonstrate efficacy after failure of combination 
therapy 128. Paclitaxel binds to tubulin, the microtubules become locked in 
polymerized state, and thus the cells are restricted from G2 to M phase transition 
leading to ceased activity of essential cell processes, such as movement, 
chromosome segregation and cell division. Another effect later observed was it 
capability to inhibit the anti-apoptosis protein Bcl-2, and thereby induces apoptosis in 
cancer cells 129,130.  
 Figure 3 - Paclitaxel structural and chemical configuration 
174
. 
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Paclitaxel shows a tetracyclic heptadecane skeleton (Figure 3) which explains its low 
hydrophilicity (0,357 μg/mL) 131. Notably, the clinical and experimental use of 
paclitaxel was limited in the beginning due to the poor solubility of the compound, 
and the demand for an excipient arose. Thus paclitaxel was primarily formulated in 
organic solvents, namely polyoxyethylated castor oil (Cremophor EL). Cremophor EL 
(CrEl) alters the pharmacokinetic profile of paclitaxel in vivo which displays an 
unpredictable non-linear plasma pharmacokinetics due to extensive binding to serum 
albumin, and consequent inactivity, broad tissue distribution, albeit incapable of 
passing blood-brain barrier, and a low half-life of 2.9±0.3 hours. Further, the effects 
are aggravated by the use of CrEl 132 133. Another combination attempting to solve 
paclitaxel’s low solubility in aqueous media is Nab-paclitaxel, where paclitaxel is 
bound to albumin nanoparticles. This formulation proved to be better at reaching 
tumors than solvent-based Paclitaxel, it showed an improvement in the treatment 
response and a slower disease progression, while reducing systemic toxicity. In fact, 
Nab-paclitaxel is already used in the treatment of breast. Nonetheless, it presents a 
much larger cost, turning the better antitumor efficacy relatively marginal 83,84.  
Henceforth, nanotechnology has become an intriguing strategy to overcome these 
drawbacks. The more obvious one is the physical and chemical protection it would 
provide by the entrapment of the pharmaceutical agent. It would also allow a higher 
injectable concentration and fully remove the excipient’s presence and toxicity. 
Paclitaxel’s pharmacokinetics would also be meliorated by the use of nanoparticle 
systems as a result of drug occlusion, a lack of epitopes detectable by the immune 
system, controlled release and possible surface modification, namely pegylation. A 
passive targeting can be achieved through the EPR effect, where particles with size 
less than circa 400 nanometers accrue in tumor tissue athwart damaged neo-
angiogenic blood vessels. An active targeting can also partake with the help of 
molecules such as folic acid, transferrin and hyaluronic acid. Both types of targeting 
will promote a better biodistribution of paclitaxel. Indeed, nanotechnology has an 
immeasurable potential in versatility and functionality modulation. They can have a 
wide range of characteristics, from being positively, neutral or negatively charged, to 
being able to co-deliver multiple agents and/or present a theranostics combination. 
They can also be engineered to respond to environment stimuli, namely pH, heat, 
light or magnetic 134. 
A large variety of nanoparticles have already been applied to the delivery of 
paclitaxel. Liposomes have shown an accentuated decrease in side effects and 
higher tumor inhibition of paclitaxel, however encapsulation efficiency is not the 
aspired since liposomes present an aqueous core which is not a good choice for 
hydrophobic drugs such as this.  As reported by Cavalli et al (0.1% release in PBS 
during 2 hours 135), Yegin et al (12.5-16.5% within 14 days 136) and Lee at al (10% in 
24 hours 137), SLNs are a better option for such drugs since they show a solely lipd 
matrix, consequently presenting higher encapsulation efficacy and slower release 
profiles 135,137,138. Although this may be true SLNs’ matrix show some drawbacks, 
eliciting an increased interest in NLCs. Since it is a fairly new area of investigation 
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within lipid-based nanoparticles, there is little information about prosperous 
paclitaxel-loaded NLC formulations, making its research imperative 139–143.  
 
1.3 AIM AND STRATEGY 
In the last years, modern society has been facing a serious health problem with the 
rising of cancer incidence. In fact, cancer is still the leading cause of death of the 
twenty-first century. Furthermore, breast cancer is the most common among women 
and it shows a relatively high number of cases in men as well. Therefore, it is 
important to invest in the research of new and improved ways to attack breast cancer 
cells without damaging healthy cells. For this purpose nanotechnology may present 
great potential. 
Paclitaxel is a drug commonly used in the treatment of breast cancer, however its 
hydrophobicity makes its administration a challenge. Once more, the key could be in 
applying nanotechnology concepts to the development of a nano-based delivery 
system for the carriage of the afore mentioned drug. The lipid matrix of NLCs 
presents a suitable environment for Pacitaxel, their surfactant-stabilized surface 
would hypothetically permit a great and long term stability in lipid media and they 
would offer occlusion and block Paclitaxel’s destructive potential until the targeted 
site was reached. Magnetic nanoparticles, in particular SPIONs, may also offer 
advantages since their superparamagnetic behavior confers hyperthermic 
capabilities, which may have an additional therapeutic effect.  
In this context, the present project aims to evaluate de cytotoxicity of SPION-loaded 
NLCs in breast cancer cells, namely MDA-MB-231 cells. 
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Chapter 2 – Materials and Methods 
 
2.1 MATERIALS 
The lipids Compritol 888 ATO and Gelucire 43/01 pellets were a kind gift from 
Gattefossé (Gattefossé, France) and Miglyol 812 was purchased from Acofarma® 
(Terrassa, Spain).  Tween® 80, Iron (II) Chloride tetra-hydrate 99%, Iron (III) Chloride 
hexa-hydrate 97% and Ammonium hydroxid 28-30%, propidium iodide were obtained 
from Sigma-Aldrich® (St. Louis, MO, USA).  Acetonitrile was purchased from VWR 
International LLC (Radnor, PA, USA). Paclitaxel was bought from LC Laboratories 
(Woburn, MA, USA).Hanks’ Balanced Salt Solution [-] CaCl2, [-] MgCl2 (HBSS), 
Dulbecco’s Modified Eagle’s Medium (DMEM), trypsin-EDTA (1x), Dulbecco’s 
Phosphate Buffered Saline 10x pH 7.4 (PBS), Fetal Bovine Serum (FBS) and 
penicillin-streptomycin (Pen-Strep) antibiotics mixture were purchased from Gibco® 
by Life Technologies™ (Invitrogen Corporation, Paisley, UK).  
All the weighting measurements were performed using a Kern ABT-120-SDM digital 
analytical balance (Kern & Sohn; Balingen, Germany).  The microwave synthesis was 
carried out in a Discover® SP microwave system (CEM Corporation; Mathews, USA), 
automated by Explorer-12 software. Ethanol 70%  was purchased from AGA (AGA-
Álcool e Géneros Alimenares S.A., Lisboa, Portugal) Milli-Q water was purified by an 
Ultra-pure water system (Milli-Q, Sartorius, Arium® Cartige 1 and 2, Sartorius Stedin 
Biotech; Göttingen, Germany) by a reverse osmosis process. 
 
2.2 METHODS 
2.2.1 NLC SYNTHESIS 
Lipid nanoparticles were prepared by a modified free organic-solvent hot 
emulsification/sonication method (Figure 4) 144. Henceforth, 70% (w/w) of Gelucire® 
43/01, 6% (w/w) of Compritol® 888 ATO, 10% (w/w) of Miglyol® 812, 12% (w/w) of 
Tween® 80 and 2% (w/w) of Paclitaxel were weighted and stored in a glass tube that 
tube was later placed in a water bath at 75⁰C since the higher melting point within the 
lipids is of 70⁰C. When all the lipids melted 15 mL of double distilled water, pre-
heated at 75⁰C were added, obtaining an opaque, white suspension, which was 
placed under the probe-sonicator at 104 W of potency during 10 minutes. The 
resulting white nanoemulsion was stored in a sealed glass vial and left to cool at 
room temperature. 
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Figure 4 - Representative diagram of the NLC synthesis process by a standalone ultrasonication 
technique. Addition of water to melted lipid, surfactant and drug (A), sonication (B) and final product (B). 
 
2.2.2 SPIONS SYNTHESIS 
SPIONs were synthesized by a process described by Mahdavi et al145, with a few 
modifications. Iron (II) Chloride tetra-hydrate (FeCl2 · 4H2O) and Iron (III) Chloride 
hexa-hydrate (FeCl3 · 6H2O), in a 1:1.8 molar ratio, were dissolved in 20 mL of 
double distilled water in a vessel under vigorous magnetic stirring. 3 mL of 
ammonium hydroxide was then rapidly added. After the precipitate settled, the vessel 
was placed inside the microwave system and the temperature set to 100⁰C, under 
maximum stirring, during 10 minutes. After the elapsed time, pressured nitrogen gas 
was injected into the system to quickly lower the temperature until 70⁰C to stop the 
reaction. Lastly, the black precipitate was collected with a strong permanent magnet, 
washed two times and suspended in 25 mL of double distilled water. The SPIONs 
were then stored in a 50 mL Falcon® at room temperature. 
 
2.2.3 SPION-LOADED NLC SYNTHESIS 
After the synthesis of NLC, as previously described in 2.2.1, 2 mL of SPIONs solution 
at room temperature were added (prepared as described in 2.2.2) obtaining an 
opaque, brown suspension, which was placed under the probe-sonicator at 104 W of 
potency during 10 minutes (Figure 5). The resulting brown nanoemulsion was stored 
in a sealed glass vial and left to cool at room temperature. 
 
)))
)))
A B C
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Figure 5 - Representative diagram of the SPION-loaded NLC synthesis process by an ultrasonication 
technique. Addition of water and SPIONS to melted lipid, surfactant and drug (A), sonication (B) and final 
product (C). 
 
2.2.4 LYOPHILIZATION 
After long periods of time, stored aqueous suspensions of NPs can form aggregates, 
and consequently become instable146.  Therefore, the water is removed in order to 
improve the stability of the system. Lyophilizatin, a commonly used industrial 
process, removes water from a frozen sample by sublimination and desorption under 
vacuum. A cryoprotectant is often added to the formulations to protect the NPs 
against freezing and desiccation stresses146. 
The NLCs were lyophilized using a programmable freeze dryer (LyoQuest -85 
laboratory freeze dryer, Telstar Grouo; Terrassa, Barcelona, Spain). Aerosil 
cryoprotectant was added to the NLCs suspensions before freezing at -80⁰C in a 
GFL Upright Freezer 6481 (GFL Gesellschaft für Labortechnik mbH; Burgwedel, 
Germany). The aerosil was screened at the following concentration: 2% of total solid 
lipid mass for its cryoprotectant efficiency. The samples were lyophilized for 48 hours 
at -80ºC and pressure of 0.5 bar. 
 
 
A B C
))) ))) )))
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2.2.5 NLCS CHARACTERIZATION 
 
2.2.5.1 Particle Size Measurements 
Dynamic light scattering (DLS) is a common technique to determine particle size in 
colloidal suspensions147. The particles suspended in a liquid solvent present random 
movement, known as Brownian movement147,148. During the particle size 
measurement by DLS technique, the NPs suspension is exposed to a laser149. Due 
to the random motion of NPs, the direction and intensity of the incident light is 
changed in a process known as scattering. Thus, from these variations the diffusion 
coefficient of NPs can be measured. Considering that NPs are spherical particles, the 
hydrodynamic diameter of the particles can be calculated from their diffusion 
coefficients149.  
The produced NLCs were characterized by its mean hydrodynamic diameter and size 
distribution (polydispersiy index) in a Particle Size Analyser (Brookhaven Instruments 
Corporation; Software: Particle Sizing v.5 Brookhaven Instruments; Holtsville, NY, 
USA). The system was operating at a fixed light incidence angle of 90º, at 25ºC, with 
a dust cut-off set to 30 and the refractive index of the particles set to 1.329. Prior to 
measurements, NPs suspensions were diluted (0.5:100) in Milli-Q water. For each 
sample a total of 6 runs of 2 minutes each was performed. 
 
2.2.5.2 Zeta Potential Measurements 
Zeta potential is a physical property exhibited by particles in suspension that 
determines its stability. Therefore, the measurement of this potential can be useful to 
characterize the stability of NPs for an extended period. When particles are in contact 
with an aqueous solution, a rearrangement of the local free ions in the solution 
occurs, creating an unequal distribution of the solution ions in close proximity to the 
particle. Henceforth, an electrical double layer is formed, which is composed by a 
compact layer and a diffuse layer150,151. In the compact layer, the ions of the solvent 
are immobile due to the strong electrostatic attraction to the particle surface. On the 
other hand, in the diffuse layer the ions are mobile, since they have a weaker 
attraction to the particle surface151 . The zeta potential is defined as the electrostatic 
potential at the boundary between the dispersion medium and the stationary layer of 
fluid attached to the dispersed particle152. Electrophoretic light scattering (ELS) is a 
common technique to measure the zeta potential. In this technique, two electrodes 
are inserted on the formulation. An incident light causes an electrophoretic 
movement of the particles in the electric field created by the electrodes153. The 
velocity of the particles motion to the electrode of the opposite charge is measured 
by the deviation of the laser light scattering spectrum, which allows the calculation of 
the zeta potential154.  
The zeta potential of all samples was determined using a Zeta Potential Analyser 
(ZetaPALS, Brookhaven Instruments Corporation; Software: PALS Zeta Potential 
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Analyser v.5 Brookhaven Instruments; Holtsville, NY, USA). The system was 
operating at 25⁰C, with a fixed light incidence angle of 90⁰. The Smoluchowski 
mathematical model was used to perform the analysis. Prior to measurements, all 
samples were diluted (0.5:100) in Milli-Q water. For each sample a total of 10 runs, 
each one with 10 cycles, was performed. 
 
2.2.6 PACLITAXEL ENCAPSULATION EFFICIENCY 
 
2.2.6.1 Indirect Method – Sodium Salicylate 
In this method, the encapsulation efficiency was determined by calculating the 
difference between the total amount of paclitaxel used to prepare the formulation and 
the amount of free paclitaxel remaining in the aqueous phase 155. Formulations were 
diluted (1:100) in a solution of sodium salicylate (0,08 mg/mL) and transferred into 
Amicon® Ultra-4 Centrifugal Filter Devices, ultracel® - 50k (50000 NMWL) (MERK 
Milipore, Ltd; Cork, Ireland). Centrifugation was performed using an Allegra® X-15R 
centrifuge (Beckman Coulter; Pasadena, CA, USA) with a spin at 3500 rpm for 30 
minutes or until complete separation between NLCs retained in the filter and the 
aqueous phase corresponding to the supernatant. The unentrapped paclitaxel was 
present in the supernatant. The EE was calculated as follows: 
 
       
                                               
                       
      
 
A calibration curve of paclitaxel dissolved in sodium salicylate was obtained in order 
to correlate absorbance with concentration. 
 
2.2.6.2 Direct Method – Acetonitrile 
In the indirect method the encapsulation efficiency of paclitaxel was determined from 
the measurement of the amount of paclitaxel encapsulated in the NPs. Formulations 
were diluted (1:100) in Milli-Q water and transferred into Amicon® Ultra-4 Centrifugal 
Filter Devices, ultracel® - 50k (50000 NMWL). Centrifugation was performed using 
the Allegra® X-15R centrifuge with a spin at 3500 rpm for 30 minutes or until 
complete separation between NLCs retained in the filter and the aqueous phase 
corresponding to the supernatant. The filter unit was centrifuged in an inverted 
position at 4500 rpm during 10 minutes to isolate the pellet were NPs with the 
encapsulated paclitaxel were present. The pellet was then dissolved in 2 mL of 
acetonitrile. The entrapped paclitaxel was present in the solution of acetonitrile. 
Sometimes the solution of acetonitrile was centrifuged one more time before 
24 
 
analysed, the centrifugation was performed in a Milipore®, Low-binding Durapore 
PVDF membrane Ultrafree®-CL, at 4500 rpm for 10 minutes or until the lipids were 
deposited. The EE was calculated as follows: 
 
        
                           
                       
      
 
A calibration curve of paclitaxel dissolved in acetonitrile was obtained in order to 
correlate absorbance with concentration. 
 
2.2.6.3 Direct Method – Ethanol 
In this method the encapsulation efficiency of paclitaxel was determined from the 
measurement of the amount of paclitaxel encapsulated in the NPs. Formulations 
were diluted (1:100) in Milli-Q water and transferred into Amicon® Ultra-4 Centrifugal 
Filter Devices, ultracel® - 50k (50000 NMWL). Centrifugation was performed using 
the Allegra® X-15R centrifuge with a spin at 3500 rpm for 30 minutes or until 
complete separation between NLCs retained in the filter and the aqueous phase 
corresponding to the supernatant. The filter unit was centrifuged in an inverted 
position at 4500 rpm during 10 minutes to isolate the pellet were NPs with the 
encapsulated paclitaxel were present. The pellet was then dissolved in 2 mL of 
ethanol and centrifuged at 4500 rpm for 30 minutes or until the lipids were deposited. 
The entrapped paclitaxel was present in the solution of ethanol. The EE was 
calculated as follows: 
 
        
                           
                       
      
 
A calibration curve of paclitaxel dissolved in ethanol was obtained in order to 
correlate absorbance with concentration. 
 
2.2.7 IN VITRO CELL VIABILITY STUDIES 
MDA-MB-231 cells were cultured at 37ºC in a 5% CO2 atmosphere (Unitherm CO2 
Incubator 3503 Uniequip; Planegg, Germany) in DMEM supplemented with 10% FBS 
and 1% Pen-Strep. When the cell culture reached a 70% to 80% confluence, was 
detached using a 0.25% trypsin-EDTA. Further, the cells were centrifuged using the 
Heraeus Multifuge X1R centrifuge (Thermo Fisher Scientific; Waltham, MA, USA) at 
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300 xg and re-suspended in fresh medium. Viable cells were counted using a 
Neubauer chamber (Improved Neubaur Bright-line, Boeco; Hamburg, Germany). 
 
2.2.7.1 MTT Assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium 
reduction assay is a colorimetric assay and it was the first homogeneous cell viability 
assay developed for a 96-well format,suitable for high throughput screening156. In this 
assay, viable cells convert MTT, a yellow tetrazole, into a purple colored formazan 
through mitochondrial activity. Dead cells lose the ability to reduce MTT into 
formazan, thus the quantity of formazan is directly proportional to the number of 
viable cells157.  
Therefore, the effect of the prepared NLCs on cell viability was evaluated using the 
MTT assay. The assay was performed for MDA-MB-231 cells. The collected cells 
were seeded in 96-well tissue culture test microplates (Tissue Culture OrPlates, 
surface treated flat bottom, Orange Scientific; Braine-l’ Alleud, Belgium) at a density 
of 5x104 cells/well in 100 μl of supplemented DMEM medium. All cells were 
incubated at 37ºC in a 5% CO2 atmosphere until the cells presented 80 to 90% of 
confluence when observed using the Motic® AE2000 Binocular Inverted Microscope 
(Motic Electric Group Co., Ltd; Xiamen, Fujian, China). Then, the culture medium was 
discarded and 100 μl of NLCs formulations with different lipid concentrations (1 
mg/mL, 5 mg/mL, 10 mg/mL, 15 mg/mL, 20 mg/mL and 25 mg/mL) were added to the 
cells, as well as a solution of Paclitaxel at different concentrations (0 µg/mL; 0,0117 
µg/mL, 0,234 µg/mL; 0,352 µg/mL; 0,586 µg/mL; 0,117 µg/mL; 2,34 µg/mL; 3,52 
µg/mL and 5,86 µg/mL). A positive control (only culture medium) was included to 
normalize and compare the results. The cells were incubated for 24 hours at 37ºC in 
a 5% CO2 atmosphere. After the incubation time, the medium was discarded and 100 
μl of MTT solution (5 mg/mL MTT in PBS stock solution diluted to a final 
concentration of 0.5 mg/mL in culture medium) was added to each well and 
incubated for 2h at 37ºC in a 5% CO2 atmosphere, to allow the formation of formazan 
crystals. Then, the medium was rejected and 100 μl of DMSO were added to the 
wells, in order to dissolve the formazan crystals. The absorbance was measured at 
590 and 630 nm using a microplate reader (BioTek Instruments; Winooski, VT, USA). 
The latter was used for background subtraction. Cell viability was determined 
according as follows: 
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2.2.7.2 Cell Viability by Flow Cytometry  
Flow cytometry is a technique that simultaneously measures and then analyses 
multiple morphological characteristics of cells, as they flow in a fluid stream through a 
beam of light. Relative size, relative granularity or internal complexity, and relative 
fluorescent intensity are the properties measured with this technology. Furthermore, 
flow cytometry is a rapid and reliable method to quantify viable cells in a cell 
suspension158.  
MDA-MB-231 cells were seeded in 48-well plates at the density of 105 cells per well 
in 300 µl of supplemented DMEM and incubated at 37⁰C in a 5% CO2 atmosphere for 
24 hours to allow cell attachment. Afterwards, the culture medium was discarded and 
300 μl of NLCs formulations with different lipid concentrations (1 mg/mL, 5 mg/mL 
and 10 mg/mL) were added to the cells, as well as Paclitaxel solution at different 
concentrations (0.13 mg/mL, 0.07 mg/mL and 0.013 mg/mL) and SPIONs solution in 
a range of concentrations (0,5 mg/mL, 0,2 mg/mL and 0,05 mg/mL) A positive control 
(culture medium) was included to normalize and compare the results. The cells were 
incubated for 24 hours, 48 hours or 72 hours at 37ºC in a 5% CO2 atmosphere. After 
incubation time, the medium was discarded and the cells were detached using a 
0.25% trypsin-EDTA. Further, the cells were centrifuged using the Heraeus Multifuge 
X1R centrifuge (Thermo Fisher Scientific; Waltham, MA, USA) at 300 xg. Then, from 
the FITC Annexin V Apoptosis Detection Kit (BioLegend®; San Diego, CA, USA), 40 
µL of Annexin V Biding Buffer, 2.5 µl of FITC Annexin V and 5 µl of 7-AAD Viability 
Staining Solution were added. After an incubation of 15 min at room temperature, 
200 µl of Annexin V Biding Buffer were added and the samples were analysed by 
flow cytometry using the BD Accuri C6 (Biosciences; Belgium). For each sample a 
minimum of 20,000 events were recorded and the cells in culture medium were used 
as a control.  
 
2.2.8 IN VITRO CELL UPTAKE 
Flow cytometry is also a useful technique to assess the NLC uptake by MDA-MB-231 
cells. Cells were seeded in 24-well plates at the density of 5x105 cells per well in 400 
µL of supplemented DMEM and incubated at 37⁰C in a 5% CO2 atmosphere for 24 
hours to allow cell attachment. Afterwards, the culture medium was discarded and 
400 μl of SPIONs-loaded NLC formulation at a 10mg/mL lipid concentration and of 
SPIONs solution at a concentration of 0.5 mg/mL. A negative control (culture 
medium) was included to normalize and compare the results. The cells were 
incubated for 24 hours, 6 hours, 3 hours, 1 hour or 30 min at 37ºC in a 5% CO2 
atmosphere. After incubation time, the medium was discarded and the cells were 
recovered by 0.25% trypsin-EDTA. Then, 5 µl of Propidium Iodide (PI) was added to 
excluded non-viable cells, and the samples were analysed by flow cytometry using 
the BD Accuri C6 (Biosciences; Belgium) recording the side scattering of each 
sample. For each sample a minimum of 20,000 events were recorded and the cells in 
culture medium were used as a control.  
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2.2.9 SCANNING ELECTRON MICROSCOPY (SEM) 
During scanning electron microscopy (SEM) a beam of high-energy electrons 
generates different signals at the surface of solid specimens. These signals reveal 
information about the sample, such as external morphology, chemical composition, 
and crystalline structure. Data is usually collected over a selected area and a 2-
dimensional image is generated159. 
Hence, the morphology of the cells treated with NLCs was evaluated by SEM using 
high resolution scanning electron microscope with X-Ray microanalysis at the 
Materials Centre of the University of Porto, Portugal (CEMUP). MDA-MB-231 cells 
were seeded in 24-well plates at the density of 5x105 cells per well in 400 µL of 
supplemented DMEM and incubated at 37⁰C in a 5% CO2 atmosphere for 24 hours to 
allow cell attachment. Afterwards, the culture medium was discarded and 400 μl of 
SPIONs-loaded NLC formulation at a 10mg/mL lipid concentration and of SPIONs 
solution at a concentration of 0.5 mg/mL. A positive control (culture medium) was 
included to compare the results. The cells were incubated for 24 hours at 37ºC in a 
5% CO2 atmosphere. After incubation time, the cells were washed and recovered 
after trypsinization. Further, the cells were attached into a microscope slide by 
centrifugation and analysed by SEM. 
 
2.2.10 STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism Software (v7 for Windows; 
GraphPad Software Inc, San Diego, CA, USA). The measurements were repeated at 
least 3 times and data expressed as mean ± SD. Data was analysed using two-way 
analysis of variance (ANOVA). A P value of <0.05 was considered statistically 
significant. 
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Chapter 3 – Results and Discussion 
 
3.1 NPS CHARACTERIZATION 
The NLC formulation prepared by a modified free organic-solvent 
emulsification/sonication method144 presented a white and milky appearance. The 
liquid suspension had a low viscosity and PAC deposits were not visible. Figure 6A 
shows the formulation which appeared stable by visual observation.  
 
SPIONs solution synthesized by an adapted process described by Mahdavi et al145 
displayed a black tint and presented no signs of aggregation or precipitation, 
remaining stable in the solution (Figure 7A). To assure magnetic character a small 
permanent magnet was put into contact with the magnetic nanoparticles during a 5 
second timeframe. Before the magnet was applied to the vial the solution is a 
completely dispersed, opaque, black suspension. At the moment of magnet exposure 
the nanoparticles are immediately attracted to the magnet, resulting in a progressive 
purification of the aqueous medium. All the SPIONs concentrate near the magnet 
forming a magnetic slurry. A solution of SPIONs is once more obtained by simple 
vigorous agitation (Figure 7). 
A B
Figure 6- Lipid nanoparticles synthesized by emulsificaion/sonication: 
NLCs placebo (A) and SPION-NLC-PAC (B). 
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Figure 7 - SPION solution response to a small permanent magnet. SPION suspension state prior to 
magnetic exposure (A), 1 second after the magnet’s placement (B), and 5 seconds of magnetic influence 
(C). 
SPION-loaded NLCs were visually beige and milky as can be perceived in Figure 
6B. The viscosity of the suspension was low and it appeared stable by visual 
observation. After synthesis, formulations were maintained in different conditions to 
evaluate the most suitable approach for long-term storage. Therefore, a batch was 
lyophilized at -80⁰C during 48 hours to obtain a powder from the suspension. To 
compare the effect of the temperature in the formulations shelf-stability another non-
lyophilized batch was divided into two vials, one was stored at room temperature and 
another one at 4⁰C. 
 
 
A
B C
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3.2 LYOPHILIZED NLCS 
The lyophilized NLCs were a light 
brown powder and were stored at 4⁰C. 
The lyophilized NLCs showed some 
aggregation as it can be seen in 
Figure 8. Moreover, when it was 
necessary to resuspend the 
lyophilized NLCs in order to perform 
stability studies such process 
demonstrated to be ineffective. As 
previously reported, aggregation of 
nanoparticles depends on the 
lyophilisation process conditions and 
on the concentration of the 
cryoprotectant. Moreover, it may also 
be affected by the system of 
nanoparticles and the freeze drying 
conditions146. An optimization of the 
amount or even the type of cryoprotectant used should be performed to improve the 
process. Theoretically, a cryoprotectant, as the name suggests, can protect the 
nanoparticle from the mechanical stress of ice. However the selection of a proper 
cryoprotectant is not straightforward, some cryoprotectants, such as sucrose, have 
even been reported to destabilize the nanoparticles146,160. The freezing rate should 
also be taken into consideration since it is an important parameter in the first step of 
freeze drying161. 
According to the literature, the higher the concentration of cryoprotectant and the 
faster the freezing rate the lesser the aggregation162, however the trend is reversed in 
several cases160,163–165. Thus, this complex process can only be developed by trial 
and error. Different concentrations and types of cryoprotectants should be tested, as 
well as various rates of freezing rates. Lyophilisation significantly improves long-term 
stability of nanoparticles, therefore optimizing this process is of upmost importance 
146,166. However, since it can be a time-consuming process, this methodology was for 
the time being, left behind. Consequently, a new approach where the stability of 
SPION-NLC hybrid suspension stored at different temperatures over time is 
evaluated was chosen. 
 
3.3 STABILITY STUDIES 
Stability studies were performed during the course of a month. Particle size, 
polydispersity and zeta potential were evaluated at weeks 0, 1, 2, 3 and 4 after the 
NPs synthesis and measured by DLS. The particle size of the SPION-NLC-PAC 
formulations stored at 4⁰C and 25⁰C was measured over time (Figure 9). In both 
Figure 8 - Lyophilized NLCs. 
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cases, and with the exception of T0, the particle size remained constant through time 
revealing sizes between 350-390 nm. The mean size diameter is of around 375 nm. 
 
Figure 9 - Evaluation of the particle size of the formulations at 4⁰C and 25⁰C over time (0 (T0), 1 (T1), 2 
(T2), 3 (T3) and 4 (T4) weeks). Bars represent the size (left Y axis). Values represent the mean ± SD of the 
readings.  
Similarly, in both storage conditions, no significant changes in polydispersity were 
observed in comparison to week 0, except for week 4 (Figure 10). Suggesting that 
the polydispersity remains stable during this period of time. The nanoformulation 
shows a low polydispersity index of around 0,237.  
 
Figure 10 - Evaluation of the polydispersity index of the formulations at 4⁰C and 25⁰C over time (0 (T0), 1 
(T1), 2 (T2), 3 (T3) and 4 (T4) weeks). Bars represent the polydispersity index (left Y axis). Values 
represent the mean ± SD of the readings. *P<0.05 relatively to the correspondent week 0. 
* * ** * * * *
*
**
*
*
*
*
*
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The zeta potential is another important parameter to evaluate NPs stability. It 
characterizes surface charge, mutually influenced by the NPs composition and the 
medium where the NPs are dispersed167. Overall, if the absolute value of zeta 
potential is above 30 mV the dispersion is considered as stable owed to the 
electrostatic repulsion between the particles. However, if the zeta potential is 
between 5 and 15 mV there is limited flocculation and in cases where it is between 0 
and 5 mV a maximum flocculation occurs168. Zeta potential values can be analysed in 
Figure 11. The SPION-NLC-PAC formulation stored at 4⁰C showed zeta potential 
values between |25| and |38| mV, displaying a decrease in absolute value of zeta 
potential. In this case, it appears the nanoformulation is losing stability trough time. 
However, when stored at 25⁰C the SPION-NLC-PAC formulation shows zeta 
potential values between |25| and |35| mV and appear to be maintaining their stability 
at an absolute value of zeta potential greater than 30 mV.  
 
Figure 11 - Evaluation of the zeta potential of the formulations at 4⁰C and 25⁰C over time (0 (T0), 1 (T1), 2 
(T2), 3 (T3) and 4 (T4) weeks). Bars represent the zeta potential (left Y axis). Values represent the mean ± 
SD of the readings. *P<0.05 relatively to the correspondent week 0. 
Overall the results suggest that the SPION-NLC-PAC formulations present a higher 
stability when stored at room temperature. 
 
3.4 ENCAPSULATION DETERMINATION OPTIMIZATION 
Selecting an encapsulation protocol must take into consideration encapsulation 
efficiency, drug/lipid ratio, drug retention, ease of preparation, sterility, ease of scale-
up, cost efficiency, as well as NP and drug stability. There are two main methods for 
the determination of encapsulation efficiency, the direct and indirect method. 
Whereas in the direct method the quantity of drug inside of the NP is directly 
measured, in the indirect method it is the amount of the non-encapsulated drug that 
is being quantified. In this report, both methods were tested. 
**
*
* * * * *
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In the indirect method the chosen solvent was sodium salicylate, due to its reported 
ability to dissolve the highly hydrophobic PAC169.  Notwithstanding, a homogeneous 
solution could not be obtained, since several concentrations were tested and none 
presented the described solubility. Notably, this method was put aside and the direct 
approach became more appealing. Initially, acetonitrile was used as the solvent in 
the direct method since it promised high solubility for PAC170. However, after several 
attempts it proved to produce undesirable calibration, making it difficult to be a 
reliable approach for the EE determination.  
Furthermore, ethanol, another solvent with high solubility for PAC170,171, was applied 
to the direct method for the EE determination of the produced NLCs. At first, the 
method seemed to have its limitations since the SPION-NLC loading capacity for 
PAC obtained was higher than 100%. In light of these results, it was concluded that 
the lipids present in the nanoformulation should be interfering with the acquired 
absorbance value. To subtract this effect, placebo formulations, equally in every way 
except for the absence of PAC, underwent the same process and a mean of their 
absorbance values (Table 2) was then subtracted to the absorbance value obtained 
in the nanoformulation of interest. 
Table 2 - Absorbance values obtained by direct method with ethanol as a solvent. 
Samples Absorbance (230 nm) Mean 
Placebo 1 0,229782 
0,21558 
Placebo 2 0,225157 
Placebo 3 0,204826 
Placebo 4 0,202554 
SPION-NLC-PAC 0,366621 
 
                                                 
 
 
     Figure 12- Calibration curve of PAC dissolved in ethanol. 
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Then with the calibration curve equation (Figure 12) where x represents the 
concentration and y the absorbance, a value for PAC’s concentration inside the 
NLCs is obtained. Finally, the EE formula was applied and a value of 77% was 
obtained. Therefore, the SPION-NLC formulations are able to entrap 77% of the PAC 
added in their synthesis. 
 
3.5 IN VITRO CELL VIABILITY STUDIES  
In order to evaluate cytotoxicity of the developed NLCs on breast cancer cells, it is 
necessary to perform cell viability studies. MDA-MB-231 cells were selected to 
assess the effect of the NLCs on cell viability.  
 
3.5.1 MTT ASSAY 
A MTT assay was performed to assess the effect of developed NLCs on cellular 
viability of breast cancer cells, namely MDA-MB-231 cells. In this assay, viability of 
the cells incubated with SPION-NLC-PAC and free PAC at different concentrations in 
relation to the mean of positive control (incubated only with culture medium).  
In Figure 13, decreased cell viability is clearly observed with the increase of SPION-
NLC-PAC’s concentration, after 24 hours treatment. Cell viability decreases to about 
50% at 5 mg/mL of NLCs in lipid, indicating high cytotoxicity of SPION-NLC-PAC to 
MDA-MB-231 cells. At concentrations of 15, 20 and 25 mg/mL cell viability was close 
to zero. 
Figure 13 - MDA-MB-231 cell viability assessed by MTT assay as a function of the different concentrations 
of SPION-NLC-PAC tested (0 mg/mL, 1 mg/mL, 5 mg/mL, 10 mg/mL, 15 mg/mL, 20 mg/mL and 25 mg/mL). 
Values represent mean ± SD. 
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In regards to free PAC (Figure 14), a decline in cell viability can also be verified.  The 
IC50 of PAC for MDA-MB-231 cells is 2,2 µM172 (1,88 µg/mL), however this assay 
shows that at a concentration of 0,0853 µg/mL of free PAC 50% of cells have died. 
On the other hand, when comparing the IC50 value of PAC for MDA-MB-231 cells 
with the results obtained when these cells are treated with SPION-NLC-PAC, at a 
lipid concentration of 5 mg/mL (where 64,5 µg/mL of PAC is expected to be present) 
50% of cell viability is lost, thus the effect of PAC on MDA-MB-231 cells is diminished 
when entrapped in SPION-NLC nanoparticles. This suggests the necessity of a 
longer period of incubation. 
 
Figure 14 - MDA-MB-231 cell viability assessed by MTT assay as a function of the different concentrations 
of free PAC tested (0 µg/mL; 0,0853 µg/mL, 0,171 µg/mL; 0,256 µg/mL; 0,427 µg/mL; 0,853 µg/mL; 1,71 
µg/mL; 2,56 µg/mL and 4,27 µg/mL). Values represent mean ± SD. 
In addition, this assay offered useful information about which concentrations to 
evaluate with flow cytometry analysis. 
 
3.5.2 FLOW CYTOMETRY  
In order to evaluate apoptosis induced by the nanoformulations, MDA-MB-231 cells 
were stained by annexin V and 7-AAD and analysed by flow cytometry. Annexin V 
binds to phosphatidylserine (PS) which translocates to the extracellular membrane 
upon initiation of apoptosis. 7-AAD has high affinity to the DNA, thus label dead cells. 
In early stages of apoptosis only annexin V is detected, late stages of apoptosis with 
loss of membrane integrity allows staining by 7-AAD as well. Viable cells show no 
staining and cells stained solely by 7-AAD are necrotic173. Cells were treated under 
different conditions, empty or void NLCs, SPION-NLCs, SPION-NLCs-PAC, free PAC 
and free SPIONs for 24 hours and 48 hours. 
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Figure 15 shows that after 24 hours of incubation the percentage of apoptotic cells 
increases with higher concentrations of SPION-NLCs-PAC and free PAC, in relation 
to untreated cells. In comparison with cells incubated with NLCs and SPION-NLCs, it 
is also noticeable that there is a greater number of apoptotic cells when MDA-MB-
231 cells are incubated with SPION-NLCs-PAC (about 5% at a concentration of 10 
mg/mL in lipid). Therefore, the drug seems to be the main reason the cells are 
becoming apoptotic. Overall, as anticipated, free PAC seems to induce apoptosis at 
a higher extent than any of the other conditions (about 12% of apoptotic cells at the 
higher tested concentration of 0,013 mg/mL). 
Figure 15 - Apoptotic MDA-MB-231 cells assessed by flow cytometry, after incubation for 24 hours with 
NLC, SPION-NLC, SPION-NLC-PAC, free PAC and free SPIONs (0 mg/mL, 1 mg/mL, 5 mg/mL and 10 
mg/mL).  Values represent mean ± SD. *P<0.05 relatively to the control. **Free PAC concentrations tested 
were the corresponding ones to the encapsulated PAC concentrations in NLC+SPION+PAC at 1, 5 and 10 
mg/mL of NPs (0,13 mg/mL, 0,07 mg/mL and 0,013 mg/mL). *** Free SPIONs concentrations tested were 
the corresponding ones to the encapsulated SPIONs in both SPION-NLC and SPION-NLC-PAC at 1, 5 and 
10 mg/mL of NPs (,5 mg/mL, 0,2 mg/mL and 0,05 mg/mL). 
After 48 hours of incubation (Figure 16), SPION-NLC-PAC remains the formulation 
that induces higher apoptotic events for MDA-MB-231 cells (about 8% of apoptotic 
cells at a 10 mg/mL concentration). It could also be emphasized that with longer of 
incubation times more apoptosis is being induced by the NPs. Free SPIONs seem to 
have a higher effect on MDA-MB-231 apoptosis after 48 hours of incubation than 
detected after only 24 hours, displaying about 13% of apoptotic cells at the higher 
tested concentration. However, free PAC seems to have little to no effect on cell 
apoptosis, which could have been a problem with the assay, so another one should 
be performed. 
This assay has shown promising results, though further investigation is clearly 
needed. An incubation period of 72h, as well as higher concentrations should be 
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evaluated in order to better assess the apoptotic mechanism of the SPION-NLC-PAC 
nanoformulation in MDA-MB-231 cells. 
 
3.6 IN VITRO CELL UPTAKE 
When NLCs are intended for breast cancer therapy it is imperative to assess their 
uptake by breast cancer cells. Therefore, the uptake of SPION-NLC and SPIONs 
alone were evaluated. Figure 17 shows that cell internalization of both SPION-NLC 
and free SPIONs occurs, being detected as early as 30 minutes after incubation. 
After 24 hours of incubation a 15% uptake of SPIONs can be observed, whereas only 
7% of SPION-NLC are internalized after the same incubation time. In fact, SPIONs 
seem to be easily internalized when compared to the SPION-NLC formulation, 
probably due to their smaller size. These results suggest that the lipids decrease the 
uptake capacity of MDA-MB-231 cells. However, it should be taken into consideration 
that the lipids are fundamental in the delivery of the drug to breast cancer cells, the 
main objective of this project. 
Figure 16 - Apoptotic MDA-MB-231 cells assessed by flow cytometry after incubation for 48 hours with 
NLC, SPION-NLC, SPION-NLC-PAC, free PAC and free SPIONs (0 mg/mL, 1 mg/mL, 5 mg/mL and 10 
mg/mL).  Values represent mean ± SD. *P<0.05 relatively to the control. 
#
 Free PAC concentrations tested 
were the corresponding ones to the encapsulated PAC concentrations in NLC+SPION+PAC at 1, 5 and 10 
mg/mL of NPs (0,13 mg/mL, 0,07 mg/mL and 0,013 mg/mL). 
##
 Free SPIONs concentrations tested were the 
corresponding ones to the encapsulated SPIONs in both SPION-NLC and SPION-NLC-PAC at 1, 5 and 10 
mg/mL of NPs (0,5 mg/mL, 0,2 mg/mL and 0,05 mg/mL). 
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Figure 18 - Nanoparticle uptake by MDA-MB-231 cells up to 24 hours. Values represent mean ± SD (n=2).. 
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Figure 17 - SEM images of the NLCs suspensions. MDA-MB-231 cells, magnification 1000X (A) and 
10000X (B). MDA-MB-231 cells after 24 hours incubation with free SPIONs, magnification 1000X (C) 
and 10000X (D). 
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3.7 SCANNING ELECTRON MICROSCOPY (SEM) 
SEM was used to evaluate the cells’ and surface topography and composition. MDA-
MB-231 cells treated with 0,5 mg/mL of free SPIONs, for 24 hours were observed. 
Figures 18A and 18B show the morphology of untreated MDA-MB-231 cells. 
Brighter spots can be detected in Figures 18C and 18D representing the SPIONs, as 
verified by the EDS spectra (Figure 19Z1), where a peak of iron is observed. 
Internalization of SPIONs by MDA-MB-231 cells can also be visualized in Figure 20, 
once again a peak of iron on the EDS spectra proves the particle inside the cell is 
indeed a SPION (Figure 20Z3). These results corroborate the results obtained with 
the uptake assay, suggesting that the MDA-MB-231 cells are able to internalize these 
SPIONs. In addition, cell morphology seems to not be affected by SPIONs uptake. 
 
 
Figure 19 - SEM images (left) and EDS spectra (right) of MDA-MB-231 cells after 24 hours incubation with 
free SPIONs, magnification 5000X. 
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Figure 20 – SEM images (left) and EDS spectra (right) of MDA-MB-231 cells after 24 hours incubation with 
free SPIONs, magnification 5000X. An internalized SPION can be observed, marked by Z3. 
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Chapter 4 – Conclusions 
 
In the present work, PAC- and SPION-loaded NLC formulation was tested as a 
potential therapeutic agent for breast cancer therapy. These nanoformulations 
presented a size of 375 nm, a polydispersity index of 0,237, indicating 
monodispersity, a zeta potential superior to |30| mV, suggesting high stability, and a 
high encapsulation efficiency of 77%. In addition, NLCs stored at both 4⁰C and 25⁰C 
showed high stability, though storage at room temperature seemed to be the better 
choice. According to the literature, lyophilized particles are proven to maintain 
stability for greater periods of time, however lyophilization of the NPs was ineffective 
and the procedure must be optimized in order to obtain any definitive conclusions. 
Internalization of the nanoparticles by MDA-MB-231 cells was proved in both the 
uptake assay and SEM. The free SPIONs were easily and more rapidly internalized 
by the cells, due to their smaller size. However, it is clear that the NLCs are indeed 
internalized by MDA-MB-231 cells. The cytotoxicity of the NLCs developed was 
assessed through MTT assays and flow cytometry. In the MTT assays cell death was 
recorded in the presence of the NLCs. Apoptosis induced by the NPs was assessed 
by flow cytometry, showing that the developed NLCs could be a valuable tool in 
breast cancer therapy.  
In summary, it is expected that the nanoformulation diminishes noxious effects and 
allows controlled release and release on-demand due to hyperthermic capabilities of 
magnetic nanoparticles. Nevertheless, further studies are required in order to 
determine their exact effect on breast cancer cells. 
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Chapter 5 – Future Work 
 
For future work, stability studies of the NLCs suspensions stored at 4⁰C and 25⁰C are 
expected to continue in order to define the NLCs shelf-time. Release studies should 
also be performed in order to understand how the drug is release through time. It is 
also important to define a lyophilisation protocol that does not compromise the NLCs 
characteristics. These studies should be conducted at both 37⁰C and 42⁰C, since the 
first would mimic the nanoparticles response in the body and the second would mimic 
the tumoral environment. But before there is the necessity to optimize PAC’s solubilty 
in sodium salycilate or another solution able to solubilize the compound. 
Functionalization of the nanoparticle surface would also be an interesting approach 
moving forward. 
Further in vitro studies should be conducted. A wider range of concentrations and 
incubation times as well as different breast cancer cell lines should be evaluated. 
Ultimately, the efficacy of the designed nanosytem must be tested in vivo in healthy 
and disease animal model.  
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